SINOVAC Secures Exclusive 2026 Influenza Vaccine Supply Contract in Chile

BEIJING, Jan. 4, 2026 — Sinovac Biotech Ltd. ("SINOVAC" or the "Company"), a leading global provider of biopharmaceutical products, has been awarded an exclusive contract under the Chilean government's 2026 global tender for seasonal influenza vaccines, with an order exceeding 8 million doses. The first batch of vaccines is scheduled to be delivered to Chile by the end of January 2026, ahead of the country's upcoming influenza season.

This award marks the second consecutive year SINOVAC has served as the sole provider for Chile's national influenza immunization efforts. The selection follows the successful execution of the 2025 program, during which SINOVAC-supplied vaccines supported the administration of 8.3 million doses, facilitating an approximately 80% vaccination rate among the nation's target populations.

SINOVAC's engagement in Chile extends beyond product supply to include multi-year clinical research collaborations. In August 2024, results from an international, multicenter clinical study of SINOVAC's quadrivalent influenza vaccine were published in the peer-reviewed journal Vaccines, demonstrating immunogenicity and safety outcomes, with antibody responses against all four influenza strains exceeding those of comparator vaccines. More recently, a Phase III study conducted in adult populations in Chile, evaluating both humoral and cellular immune responses, was published in Nature Communications, further supporting the scientific basis of the vaccine's immunogenicity and safety.

To date, SINOVAC's influenza vaccines have been authorized in nearly 20 countries and regions. With cumulative global deliveries exceeding 120 million doses, the Company continues to strengthen its role in global respiratory disease prevention through consistent manufacturing quality and a robust evidence-based clinical program.

About SINOVAC

Sinovac Biotech Ltd. (SINOVAC) is a global biopharmaceutical company headquartered in China. Guided by its mission to “Supply Vaccines to Eliminate Human Diseases,” the Company is dedicated to the research, development, manufacturing and supply of vaccines and related biological products, providing vaccine products and related solutions for disease prevention and control worldwide.

SINOVAC has a diversified vaccine portfolio across multiple disease areas, including influenza, viral hepatitis, varicella, hand, foot and mouth disease (HFMD), poliomyelitis, rabies, tetanus, and pneumococcal disease. Three of SINOVAC's vaccines have been prequalified by the World Health Organization: the inactivated hepatitis A vaccine Healive®, the Sabin-strain inactivated poliomyelitis  vaccine (sIPV), and the live attenuated varicella vaccine.

SINOVAC has extensive experience in vaccine research, development and commercialization for emerging infectious diseases and public health emergencies. The Company initiated vaccine R&D in response to major public health threats, including SARS, H5N1, H1N1, and COVID-19, and developed the world's first inactivated SARS vaccine (with Phase I clinical trials completed), China's first inactivated pandemic influenza vaccine against H5N1 (Panflu®), the world's first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the world's most widely used inactivated COVID-19 vaccine. Beyond its marketed portfolio, SINOVAC continues to advance its R&D pipeline, spanning combination vaccines, recombinant protein vaccines, mRNA technologies, antibody-based products, and other next-generation technologies and product platforms, while expanding its capabilities in disease prevention and biopharmaceuticals.

With a long-standing commitment to innovation and global health, SINOVAC continues to deepen collaboration with research institutions, international organizations, and local partners while expanding its global presence. Through technological collaboration, localized production, and industrial partnerships, the Company aims to improve access to high-quality vaccines across regions, better address local disease prevention and healthcare needs, and strengthen preparedness for future public health challenges.

For more information, please see the Company's website at www.sinovac.com.